S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:SRRK

Scholar Rock (SRRK) Stock Price, News & Analysis

$15.45
+0.45 (+3.00%)
(As of 03/27/2024 ET)
Today's Range
$15.13
$15.54
50-Day Range
$13.20
$17.20
52-Week Range
$5.56
$21.17
Volume
594,235 shs
Average Volume
1.24 million shs
Market Capitalization
$1.20 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.20

Scholar Rock MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
56.6% Upside
$24.20 Price Target
Short Interest
Bearish
13.54% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.92
Upright™ Environmental Score
News Sentiment
0.08mentions of Scholar Rock in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$769,490 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.96) to ($1.77) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.56 out of 5 stars

Medical Sector

101st out of 939 stocks

Biological Products, Except Diagnostic Industry

14th out of 151 stocks

SRRK stock logo

About Scholar Rock Stock (NASDAQ:SRRK)

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

SRRK Stock Price History

SRRK Stock News Headlines

The Small Biotech with a BIG Cancer Solution
There's a new cancer treatment so precise, it's been called a "smart bomb." One that can deliver a toxic payload directly to tumors while bypassing healthy cells.
SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp (2QK.BE)
Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Scholar Rock Reports Wider Loss For Full Year
SRRK Apr 2024 10.000 put
SRRK Apr 2024 22.500 call
SRRK Oct 2024 5.000 call
SRRK Jul 2024 10.000 call
SRRK Oct 2024 25.000 call
SRRK Mar 2024 7.500 put
Scholar Rock Holding Corp.
SRRK Mar 2024 15.000 call
SRRK Mar 2024 15.000 put
See More Headlines
Receive SRRK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Scholar Rock and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:SRRK
Employees
150
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$24.20
High Stock Price Target
$30.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+56.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-165,790,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$33.19 million
Book Value
$3.12 per share

Miscellaneous

Free Float
57,465,000
Market Cap
$1.20 billion
Optionable
Optionable
Beta
0.89
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Edward H. Myles MBAMr. Edward H. Myles MBA (Age 52)
    CFO, COO & Treasurer
    Comp: $668.49k
  • Ms. Junlin Ho J.D. (Age 45)
    General Counsel & Corporate Secretary
    Comp: $563.73k
  • Mr. Mo Qatanani Ph.D. (Age 50)
    Chief Scientific Officer
  • Rushmie Nofsinger
    Vice President of Corporate Affairs & Investor Relations
  • Ms. Caryn Parlavecchio (Age 52)
    Chief Human Resources Officer
  • Ms. Lisa Amaya Price
    Senior Vice President of Human Resources
  • Ms. Erin Moore (Age 49)
    Senior Vice President of Finance
  • Mr. Ryan Iarrobino
    Senior Vice President of Clinical Development & Operations
  • Dr. Jing L. Marantz M.B.A. (Age 59)
    M.D., Ph.D., Chief Medical Officer
  • Ms. Tracey M. Sacco M.B.A. (Age 48)
    Chief Commercial Officer

SRRK Stock Analysis - Frequently Asked Questions

Should I buy or sell Scholar Rock stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SRRK shares.
View SRRK analyst ratings
or view top-rated stocks.

What is Scholar Rock's stock price target for 2024?

5 analysts have issued 1-year target prices for Scholar Rock's shares. Their SRRK share price targets range from $20.00 to $30.00. On average, they expect the company's share price to reach $24.20 in the next twelve months. This suggests a possible upside of 56.6% from the stock's current price.
View analysts price targets for SRRK
or view top-rated stocks among Wall Street analysts.

How have SRRK shares performed in 2024?

Scholar Rock's stock was trading at $18.80 on January 1st, 2024. Since then, SRRK shares have decreased by 17.8% and is now trading at $15.45.
View the best growth stocks for 2024 here
.

When is Scholar Rock's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our SRRK earnings forecast
.

How were Scholar Rock's earnings last quarter?

Scholar Rock Holding Co. (NASDAQ:SRRK) announced its earnings results on Tuesday, November, 7th. The company reported ($0.53) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.53). During the same period last year, the business posted ($0.55) earnings per share.

What other stocks do shareholders of Scholar Rock own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Scholar Rock investors own include Fulcrum Therapeutics (FULC), Coherus BioSciences (CHRS), CTI BioPharma (CTIC), Exelixis (EXEL), GlycoMimetics (GLYC), Nektar Therapeutics (NKTR), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV) and Atara Biotherapeutics (ATRA).

When did Scholar Rock IPO?

Scholar Rock (SRRK) raised $76 million in an initial public offering on Thursday, May 24th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Scholar Rock's major shareholders?

Scholar Rock's stock is owned by many different retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (11.54%), Price T Rowe Associates Inc. MD (11.54%), Vanguard Group Inc. (3.96%), Vanguard Group Inc. (3.96%), Bellevue Group AG (3.01%) and Goldman Sachs Group Inc. (1.98%). Insiders that own company stock include Amir Nashat, Caryn Parlavecchio, Edward H Myles, Jay T Backstrom, Jeffrey S Flier, Junlin Ho, Mo Qatanani, Public Equities LP Invus and Samsara Biocapital Gp, Llc.
View institutional ownership trends
.

How do I buy shares of Scholar Rock?

Shares of SRRK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SRRK) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners